Chronic myelogenous leukemia (CML) is a cancer of the hematopoietic system and is initiated and driven by the product of the BCR-ABL fusion gene [1]–[4]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.